MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

Molecular Immunology

Volumn 43, Issue 8, 2006, Pages 1129-1143

  Brischwein, Klaus ^a   Schlereth, Bernd ^a   Guller, Benjamin ^a   Steiger, Carola ^a   Wolf, Andreas ^a   Lutterbuese, Ralf ^a   Offner, Sonja ^a   Locher, Mathias ^a   Urbig, Thomas ^a   Raum, Tobias ^a   Kleindienst, Petra ^a   Wimberger, Pauline ^c   Kimmig, Rainer ^c   Fichtner, Iduna ^b   Kufer, Peter ^a   Hofmeister, Robert ^a   Da Silva, Antonio J ^a,d   Baeuerle, Patrick A ^a  

^a MICROMET AG   (Germany)

^b Experimental Pharmacology and Oncology GmbH   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d Direvo Biotech AG   (Germany)

Author keywords

BiTE; CD3; Ep CAM; Single chain antibody; Tumor; Xenograft model

Indexed keywords

BISPECIFIC ANTIBODY; CD3 ANTIBODY; CD69 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; MT 110; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TUMOR CELL LINE; TUMOR GROWTH;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD19; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 28744445538     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2005.07.034     Document Type: Article

References (63)

1. C. Adrain, B.M. Murphy, and S.J. Martin Molecular ordering of the caspase activation cascade initiated by the CTL/NK protease granzyme B J. Biol. Chem. 280 2004 4663 4673
2. J.L. Antunes, T.N. Toporcov, and F.P. de Andrade Trends and patterns of cancer mortality in European countries Eur. J. Cancer Prev. 12 2003 367 372
3. H. Appel, L. Gauthier, J. Pyrdol, and K.W. Wucherpfennig Kinetics of T-cell receptor binding by bivalent HLA-DR. Peptide complexes that activate antigen-specific human T-cells J. Biol. Chem. 275 2000 312 321
4. P.A. Baeuerle, P. Kufer, and R. Lutterbuse Bispecific antibodies for polyclonal T-cell engagement Curr. Opin. Mol. Ther. 5 2003 413 419
5. M. Balzar, M.J. Winter, C.J. de Boer, and S.V. Litvinov The biology of the 17-1A antigen (Ep-CAM) J. Mol. Med. 77 1999 699 712
6. G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99 2002 754 758
7. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat. Med. 6 2000 443 446
8. B. Cochlovius, S.M. Kipriyanov, M.J. Stassar, O. Christ, J. Schuhmacher, G. Strauss, G. Moldenhauer, and M. Little Treatment of human B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells J. Immunol. 165 2000 888 895
9. S. Dall'Ozzo, S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, H. Watier, and G. Thibault Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship Cancer Res. 64 2004 4664 4669
10. T.A. Davis, M.S. Kaminski, J.P. Leonard, F.J. Hsu, M. Wilkinson, A. Zelenetz, R.L. Wahl, S. Kroll, M. Coleman, M. Goris, R. Levy, and S.J. Knox The radioisotope contributes significantly to the activity of radioimmunotherapy Clin. Cancer Res. 10 2004 7792 7798
11. J.S. de Bono, A.W. Tolcher, A. Forero, G.F. Vanhove, C. Takimoto, R.J. Bauer, L.A. Hammond, A. Patnaik, M.L. White, S. Shen, M.B. Khazaeli, E.K. Rowinsky, and A.F. LoBuglio ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas Clin. Cancer Res. 10 2004 7555 7565
12. K.E. De Visser, T.N. Schumacher, and A.M. Kruisbeek CD8+ T cell tolerance and cancer immunotherapy J. Immunother. 26 2003 1 11
13. T. Dreier, P.A. Baeuerle, I. Fichtner, M. Grun, B. Schlereth, G. Lorenczewski, P. Kufer, R. Lutterbuse, G. Riethmuller, P. Gjorstrup, and R.C. Bargou T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct J. Immunol. 170 2003 4397 4402
14. T. Dreier, G. Lorenczewski, C. Brandl, P. Hoffmann, U. Syring, F. Hanakam, P. Kufer, G. Riethmuller, R. Bargou, and P.A. Baeuerle Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody Int. J. Cancer 100 2002 690 697
15. M.E. Dudley, and S.A. Rosenberg Adoptive-cell-transfer therapy for the treatment of patients with cancer Nat. Rev. Cancer 3 2003 666 675
16. M.E. Dudley, J.R. Wunderlich, J.C. Yang, R.M. Sherry, S.L. Topalian, N.P. Restifo, R.E. Royal, U. Kammula, D.E. White, S.A. Mavroukakis, L.J. Rogers, G.J. Gracia, S.A. Jones, D.P. Mangiameli, M.M. Pelletier, J. Gea-Banacloche, M.R. Robinson, D.M. Berman, A.C. Filie, A. Abati, and S.A. Rosenberg Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J. Clin. Oncol. 23 2005 2346 2357
17. R.D. Faulkner, C. Craddock, J.L. Byrne, P. Mahendra, A.P. Haynes, H.G. Prentice, M. Potter, A. Pagliuca, A. Ho, S. Devereux, G. McQuaker, G. Mufti, J.L. Yin, and N.H. Russell BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients Blood 103 2004 428 434
18. D. Flieger, P. Kufer, I. Beier, T. Sauerbruch, and I.G. Schmidt-Wolf A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells Cancer Immunol. Immunother. 49 2000 441 448
19. F.M. Foss Immunologic mechanisms of antitumor activity Semin. Oncol. 29 2002 5 11
20. R.R. Furman, M. Coleman, and J.P. Leonard Epratuzumab in non-Hodgkin's lymphomas Curr. Treat Options Oncol. 5 2004 283 288
21. R. Gennari, S. Menard, F. Fagnoni, L. Ponchio, M. Scelsi, E. Tagliabue, F. Castiglioni, L. Villani, C. Magalotti, N. Gibelli, B. Oliviero, B. Ballardini, G. Da Prada, A. Zambelli, and A. Costa Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 Clin. Cancer Res. 10 2004 5650 5655
22. L.H. Glimcher, M.J. Townsend, B.M. Sullivan, and G.M. Lord Recent developments in the transcriptional regulation of cytolytic effector cells Nat. Rev. Immunol. 4 2004 900 911
23. A.J. Grillo-Lopez, C.A. White, C. Varns, D. Shen, A. Wei, A. McClure, and B.K. Dallaire Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma Semin. Oncol. 26 1999 66 73
24. G. Hale, M.J. Zhang, D. Bunjes, H.G. Prentice, D. Spence, M.M. Horowitz, A.J. Barrett, and H. Waldmann Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection Blood 92 1998 4581 4590
25. D.G. Hoel, D.L. Davis, A.B. Miller, E.J. Sondik, and A.J. Swerdlow Trends in cancer mortality in 15 industrialized countries, 1969-1986 J. Natl. Cancer Inst. 84 1992 313 320
26. H.L. Howe, P.A. Wingo, M.J. Thun, L.A. Ries, H.M. Rosenberg, E.G. Feigal, and B.K. Edwards Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends J. Natl. Cancer Inst. 93 2001 824 842
27. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, and F. Kabbinavar Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335 2342
28. T.D. Jones, M. Hanlon, B.J. Smith, C.T. Heise, P.D. Nayee, D.A. Sanders, A. Hamilton, C. Sweet, E. Unitt, G. Alexander, K.M. Lo, S.D. Gillies, F.J. Carr, and M.P. Baker The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection J. Interferon Cytokine Res. 24 2004 560 572
29. M.Y. Khalil, J.R. Grandis, and D.M. Shin Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer Expert Rev. Anticancer Ther. 3 2003 367 380
30. J.H. Kim, D. Herlyn, K.K. Wong, D.C. Park, J.O. Schorge, K.H. Lu, S.J. Skates, D.W. Cramer, R.S. Berkowitz, and S.C. Mok Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer Clin. Cancer Res. 9 2003 4782 4791
31. P.D. Kottaridis, D.W. Milligan, R. Chopra, R.K. Chakraverty, S. Chakrabarti, S. Robinson, K. Peggs, S. Verfuerth, R. Pettengell, J.C. Marsh, S. Schey, P. Mahendra, G.J. Morgan, G. Hale, H. Waldmann, M.C. de Elvira, C.D. Williams, S. Devereux, D.C. Linch, A.H. Goldstone, and S. Mackinnon In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 96 2000 2419 2425
32. P. Kufer, R. Lutterbuse, and P.A. Baeuerle A revival of bispecific antibodies Trends Biotechnol. 22 2004 238 244
33. P. Kufer, M. Mack, R. Gruber, R. Lutterbuse, F. Zettl, and G. Riethmuller Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer Cancer Immunol. Immunother. 45 1997 193 197
34. J.P. Leonard, M. Coleman, J.C. Ketas, A. Chadburn, R. Furman, M.W. Schuster, E.J. Feldman, M. Ashe, S.J. Schuster, W.A. Wegener, H.J. Hansen, H. Ziccardi, M. Eschenberg, U. Gayko, S.Z. Fields, A. Cesano, and D.M. Goldenberg Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results Clin. Cancer Res. 10 2004 5327 5334
35. A. Loffler, M. Gruen, C. Wuchter, F. Schriever, P. Kufer, T. Dreier, F. Hanakam, P.A. Baeuerle, K. Bommert, L. Karawajew, B. Dorken, and R.C. Bargou Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct Leukemia 17 2003 900 909
36. A. Loffler, P. Kufer, R. Lutterbuse, F. Zettl, P.T. Daniel, J.M. Schwenkenbecher, G. Riethmuller, B. Dorken, and R.C. Bargou A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes Blood 95 2000 2098 2103
37. M. Mack, R. Gruber, S. Schmidt, G. Riethmuller, and P. Kufer Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity J. Immunol. 158 1997 3965 3970
38. M. Mack, G. Riethmuller, and P. Kufer A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity Proc. Natl. Acad. Sci. U.S.A. 92 1995 7021 7025
39. D.G. Maloney Mechanism of action of rituximab Anticancer Drugs 12 Suppl. 2 2001 S1 S4
40. P. Matar, F. Rojo, R. Cassia, G. Moreno-Bueno, S. Di Cosimo, J. Tabernero, M. Guzman, S. Rodriguez, J. Arribas, J. Palacios, and J. Baselga Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting Clin. Cancer Res. 10 2004 6487 6501
41. G. Moldenhauer, F. Momburg, P. Moller, R. Schwartz, and G.J. Hammerling Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker Br. J. Cancer 56 1987 714 721
42. F. Momburg, G. Moldenhauer, G.J. Hammerling, and P. Moller Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues Cancer Res. 47 1987 2883 2891
43. S. Mosolits, K. Markovic, J.E. Frodin, L. Virving, C.G. Magnusson, M. Steinitz, J. Fagerberg, and H. Mellstedt Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients Clin. Cancer Res. 10 2004 5391 5402
44. M. Munz, C. Kieu, B. Mack, B. Schmitt, R. Zeidler, and O. Gires The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation Oncogene 23 2004 5748 5758
45. A. Nagler, R. Condiotti, A. Lubina, and V.R. Deutsch Enhancement of megakaryocytopoiesis by Campath-1G-treated natural killer cells Bone Marrow Transplant. 20 1997 525 531
46. S. Naundorf, S. Preithner, P. Mayer, S. Lippold, A. Wolf, F. Hanakam, I. Fichtner, P. Kufer, T. Raum, G. Riethmuller, P.A. Baeuerle, and T. Dreier In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment Int. J. Cancer 100 2002 101 110
47. S. Offner, R. Hofmeister, A. Romaniuk, P. Kufer, and P.A. Baeuerle Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells Mol. Immunol. 43 2006 763 771
48. W.A. Osta, Y. Chen, K. Mikhitarian, M. Mitas, M. Salem, Y.A. Hannun, D.J. Cole, and W.E. Gillanders EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy Cancer Res. 64 2004 5818 5824
49. M.D. Pegram, T. Pienkowski, D.W. Northfelt, W. Eiermann, R. Patel, P. Fumoleau, E. Quan, J. Crown, D. Toppmeyer, M. Smylie, A. Riva, S. Blitz, M.F. Press, D. Reese, M.A. Lindsay, and D.J. Slamon Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer J. Natl. Cancer Inst. 96 2004 759 769
50. N. Porakishvili, L. Kardava, A.P. Jewell, K. Yong, M.J. Glennie, A. Akbar, and P.M. Lydyard Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway Haematologica 89 2004 435 443
51. M. Prang, S. Preithner, K. Brischwein, P. Göster, A. Wöppel, J. Müller, C. Carola Steiger, M. Malte Peters, P. Baeuerle, and A. da Silva Cellular and complement-dependent cytotoxicity of Ep-CAM specific monoclonal antibody MT201 against breast cancer cell lines Br. J. Cancer 92 2005 342 349
52. T. Raum, R. Gruber, G. Riethmuller, and P. Kufer Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens Cancer Immunol. Immunother. 50 2001 141 150
53. G. Riethmuller, E. Schneider-Gadicke, G. Schlimok, W. Schmiegel, R. Raab, K. Hoffken, R. Gruber, H. Pichlmaier, H. Hirche, and R. Pichlmayr Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group Lancet 343 1994 1177 1183
54. B. Schlereth, I. Fichtner, G. Lorenczewski, P. Kleindienst, K. Brischwein, A. da Silva, P. Kufer, R. Lutterbuese, I. Junghahn, S. Kasimir-Bauer, P. Wimberger, R. Kimmig, and P.A. Baeuerle Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct Cancer Res. 65 2005 2882 2889
55. M.R. Smith Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance Oncogene 22 2003 7359 7368
56. G. Spizzo, P. Obrist, C. Ensinger, I. Theurl, M. Dunser, A. Ramoni, E. Gunsilius, G. Eibl, G. Mikuz, and G. Gastl Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer Int. J. Cancer 98 2002 883 888
57. G. Spizzo, P. Went, S. Dirnhofer, P. Obrist, R. Simon, H. Spichtin, R. Maurer, U. Metzger, B. Von Castelberg, R. Bart, S. Stopatschinskaya, O.R. Kochli, P. Haas, F. Mross, M. Zuber, H. Dietrich, S. Bischoff, M. Mirlacher, G. Sauter, and G. Gastl High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer Breast Cancer Res. Treat. 86 2004 207 213
58. C. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher, D.J. Slamon, M. Murphy, W.F. Novotny, M. Burchmore, S. Shak, and S.J. Stewart First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur. J. Cancer 37 Suppl 1 2001 S25 S29
59. W.K. Weng, and R. Levy Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma J. Clin. Oncol. 21 2003 3940 3947
60. P. Wimberger, W. Xiang, D. Mayr, J. Diebold, T. Dreier, P.A. Baeuerle, and R. Kimmig Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody Int. J. Cancer 105 2003 241 248
61. M.J. Winter, B. Nagelkerken, A.E. Mertens, H.A. Rees-Bakker, I.H. Briaire-de Bruijn, and S.V. Litvinov Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak Exp. Cell. Res. 285 2003 50 58
62. J.T. Wong, A.A. Eylath, I. Ghobrial, and R.B. Colvin The mechanism of anti-CD3 monoclonal antibodies. Mediation of cytolysis by inter-T cell bridging Transplantation 50 1990 683 689
63. J. Xiang, Z. Pan, S. Attah-Poku, L. Babiuk, Y. Zhang, and E. Liu Production of hybrid bispecific antibody recognizing human colorectal carcinoma and CD3 antigen Mol. Biother. 4 1992 15 23